
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
People in Britain Say Find Aliens, Cure Cancer
Author(s)OBTN
A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.
Advertisement
A recent poll conducted by Britain’s Royal Society found that what Britons want most is a vaccine that will prevent cancer, with nearly 80% of respondents selecting it as their top priority for science. Of the 2000 people surveyed, 60% picked HIV/AIDS prevention as their next choice. Although 44% expressed a belief in aliens and more than one-third think scientists should be trying to find and contact them, less than 10% identified space exploration as a top priority for science.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Related to this article

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.

VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5

